Finance

Plus Therapeutics Stock Rises on Reyobiq FDA Orphan Drug Designation

Plus Therapeutics shares surged Friday after Benzinga reported the FDA granted Orphan Drug Designation for Reyobiq to treat pediatric malignant gliomas. The designation, if maintained through approval, could yield seven years of marketing exclusivity and signals regulatory traction for the radiopharmaceutical. Regulatory progress alongside ongoing Phase 1/2 activity keeps the stock in focus for investors weighing risk in a small-cap biotech.

📅 April 10, 2026
⏱️ 2 min read
Plus Therapeutics Stock Rises on Reyobiq FDA Orphan Drug Designation

Key Takeaways

  • FDA Orphan Drug Designation for Reyobiq could provide seven years of marketing exclusivity upon approval.
  • The designation reportedly includes pediatric ependymoma, expanding Reyobiq's potential CNS indications.
  • Regulatory progress includes a Type B FDA meeting and encouraging data from the ReSPECT-LM trial.
  • AMA approved a CPT code for CNSide CSF tumor cell enumeration effective July 1, potentially aiding reimbursement.
  • PSTV traded around $5.24 on Friday, near its 20-day SMA, in reaction to the news.

People Involved

Entities Involved

  • Plus Therapeutics, Inc. (PSTV) Clinical-stage biotech focused on radiopharmaceuticals for CNS cancers
  • U.S. Food and Drug Administration (FDA) Regulatory agency granting Orphan Drug Designation (per report)
  • American Medical Association (AMA) Issuer of CPT code for CNSide CSF tumor cell enumeration

MarketMoodz Analysis

The Orphan Drug Designation for Reyobiq creates a potential seven-year market exclusivity window upon approval, a meaningful economic moat for a small-cap radiopharmaceutical program and a potential uplift to investor valuation if the program advances. However, the claim is based on Benzinga coverage and has not been independently verified; treat the designation as a catalyst with regulatory uncertainty until confirmed.

In historical terms, orphan-designation events have often provided upside for biotech names without guaranteeing clinical success. Ongoing regulatory interactions (Type B meeting) and IND discussions, alongside early trial signals (ReSPECT-LM), suggest momentum, but liquidity, funding needs, and competitive pressure in pediatric CNS cancers remain meaningful risk factors. Investors should monitor upcoming trial readouts, regulatory milestones, and reimbursement developments (CNSide CPT code) to gauge upside versus risk.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial